Cost-effectiveness analysis of quadrivalent influenza vaccine in Spain.
Identifieur interne : 000158 ( Main/Exploration ); précédent : 000157; suivant : 000159Cost-effectiveness analysis of quadrivalent influenza vaccine in Spain.
Auteurs : Amos García [Espagne] ; Raúl Ortiz De Lejarazu [Espagne] ; Jordi Reina [Espagne] ; Daniel Callejo [Espagne] ; Jesús Cuervo [Espagne] ; Raúl Morano Larragueta [Espagne]Source :
- Human vaccines & immunotherapeutics [ 2164-554X ] ; 2016.
Descripteurs français
- KwdFr :
- Adolescent (MeSH), Adulte (MeSH), Adulte d'âge moyen (MeSH), Analyse coût-bénéfice (MeSH), Coûts indirects de la maladie (MeSH), Enfant (MeSH), Enfant d'âge préscolaire (MeSH), Espagne (épidémiologie), Femelle (MeSH), Grippe humaine (prévention et contrôle), Grippe humaine (économie), Grippe humaine (épidémiologie), Grossesse (MeSH), Humains (MeSH), Jeune adulte (MeSH), Mâle (MeSH), Nourrisson (MeSH), Sujet âgé (MeSH), Sujet âgé de 80 ans ou plus (MeSH), Vaccins antigrippaux (administration et posologie), Vaccins antigrippaux (immunologie), Vaccins antigrippaux (économie).
- MESH :
- administration et posologie : Vaccins antigrippaux.
- immunologie : Vaccins antigrippaux.
- prévention et contrôle : Grippe humaine.
- économie : Grippe humaine, Vaccins antigrippaux.
- épidémiologie : Espagne, Grippe humaine.
- Adolescent, Adulte, Adulte d'âge moyen, Analyse coût-bénéfice, Coûts indirects de la maladie, Enfant, Enfant d'âge préscolaire, Femelle, Grossesse, Humains, Jeune adulte, Mâle, Nourrisson, Sujet âgé, Sujet âgé de 80 ans ou plus.
English descriptors
- KwdEn :
- Adolescent (MeSH), Adult (MeSH), Aged (MeSH), Aged, 80 and over (MeSH), Child (MeSH), Child, Preschool (MeSH), Cost of Illness (MeSH), Cost-Benefit Analysis (MeSH), Female (MeSH), Humans (MeSH), Infant (MeSH), Influenza Vaccines (administration & dosage), Influenza Vaccines (economics), Influenza Vaccines (immunology), Influenza, Human (economics), Influenza, Human (epidemiology), Influenza, Human (prevention & control), Male (MeSH), Middle Aged (MeSH), Pregnancy (MeSH), Spain (epidemiology), Young Adult (MeSH).
- MESH :
- chemical , administration & dosage : Influenza Vaccines.
- chemical , economics : Influenza Vaccines.
- chemical , immunology : Influenza Vaccines.
- economics : Influenza, Human.
- epidemiology : Influenza, Human, Spain.
- prevention & control : Influenza, Human.
- Adolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, Cost of Illness, Cost-Benefit Analysis, Female, Humans, Infant, Male, Middle Aged, Pregnancy, Young Adult.
Abstract
Influenza has a major impact on healthcare systems and society, but can be prevented using vaccination. The World Health Organization (WHO) currently recommends that influenza vaccines should include at least two virus A and one virus B lineage (trivalent vaccine; TIV). A new quadrivalent vaccine (QIV), which includes an additional B virus strain, received regulatory approval and is now recommended by several countries. The present study estimates the cost-effectiveness of replacing TIVs with QIV for risk groups and elderly population in Spain. A static, lifetime, multi-cohort Markov model with a one-year cycle time was adapted to assess the costs and health outcomes associated with a switch from TIV to QIV. The model followed a cohort vaccinated each year according to health authority recommendations, for the duration of their lives. National epidemiological data allowed the determination of whether the B strain included in TIVs matched the circulating one. Societal perspective was considered, costs and outcomes were discounted at 3% and one-way and probabilistic sensitivity analyses were performed. Compared to TIVs, QIV reduced more influenza cases and influenza-related complications and deaths during periods of B-mismatch strains in the TIV. The incremental cost-effectiveness ratio (ICER) was 8,748€/quality-adjusted life year (QALY). One-way sensitivity analysis showed mismatch with the B lineage included in the TIV was the main driver for ICER. Probabilistic sensitivity analysis shows ICER below 30,000€/QALY in 96% of simulations. Replacing TIVs with QIV in Spain could improve influenza prevention by avoiding B virus mismatch and provide a cost-effective healthcare intervention.
DOI: 10.1080/21645515.2016.1182275
PubMed: 27184622
PubMed Central: PMC5027707
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cost-effectiveness analysis of quadrivalent influenza vaccine in Spain.</title><author><name sortKey="Garcia, Amos" sort="Garcia, Amos" uniqKey="Garcia A" first="Amos" last="García">Amos García</name><affiliation wicri:level="1"><nlm:affiliation>a Servicio Epidemiología y Prevención , DG Salud Pública Servicio Canario de Salud , Las Palmas , Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>a Servicio Epidemiología y Prevención , DG Salud Pública Servicio Canario de Salud , Las Palmas </wicri:regionArea><wicri:noRegion>Las Palmas </wicri:noRegion></affiliation></author><author><name sortKey="Ortiz De Lejarazu, Raul" sort="Ortiz De Lejarazu, Raul" uniqKey="Ortiz De Lejarazu R" first="Raúl" last="Ortiz De Lejarazu">Raúl Ortiz De Lejarazu</name><affiliation wicri:level="1"><nlm:affiliation>b National Influenza Center , Servicio Microbiología Hospital Clínico Valladolid , Valladolid , Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>b National Influenza Center , Servicio Microbiología Hospital Clínico Valladolid , Valladolid </wicri:regionArea><wicri:noRegion>Valladolid </wicri:noRegion></affiliation></author><author><name sortKey="Reina, Jordi" sort="Reina, Jordi" uniqKey="Reina J" first="Jordi" last="Reina">Jordi Reina</name><affiliation wicri:level="1"><nlm:affiliation>c Centro de Referencia de la Gripe , Servicio Microbiología Hospital Universitario Son Espases , Palma de Mallorca , Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>c Centro de Referencia de la Gripe , Servicio Microbiología Hospital Universitario Son Espases , Palma de Mallorca </wicri:regionArea><wicri:noRegion>Palma de Mallorca </wicri:noRegion></affiliation></author><author><name sortKey="Callejo, Daniel" sort="Callejo, Daniel" uniqKey="Callejo D" first="Daniel" last="Callejo">Daniel Callejo</name><affiliation wicri:level="1"><nlm:affiliation>d BAP Health Outcomes Research , Oviedo , Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>d BAP Health Outcomes Research , Oviedo </wicri:regionArea><wicri:noRegion>Oviedo </wicri:noRegion></affiliation></author><author><name sortKey="Cuervo, Jesus" sort="Cuervo, Jesus" uniqKey="Cuervo J" first="Jesús" last="Cuervo">Jesús Cuervo</name><affiliation wicri:level="1"><nlm:affiliation>d BAP Health Outcomes Research , Oviedo , Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>d BAP Health Outcomes Research , Oviedo </wicri:regionArea><wicri:noRegion>Oviedo </wicri:noRegion></affiliation></author><author><name sortKey="Morano Larragueta, Raul" sort="Morano Larragueta, Raul" uniqKey="Morano Larragueta R" first="Raúl" last="Morano Larragueta">Raúl Morano Larragueta</name><affiliation wicri:level="1"><nlm:affiliation>e Dpto. Evaluación de Medicamentos , GSK , Madrid , Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>e Dpto. Evaluación de Medicamentos , GSK , Madrid </wicri:regionArea><wicri:noRegion>Madrid </wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:27184622</idno><idno type="pmid">27184622</idno><idno type="doi">10.1080/21645515.2016.1182275</idno><idno type="pmc">PMC5027707</idno><idno type="wicri:Area/Main/Corpus">00132</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">00132</idno><idno type="wicri:Area/Main/Curation">000132</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000132</idno><idno type="wicri:Area/Main/Exploration">000132</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Cost-effectiveness analysis of quadrivalent influenza vaccine in Spain.</title><author><name sortKey="Garcia, Amos" sort="Garcia, Amos" uniqKey="Garcia A" first="Amos" last="García">Amos García</name><affiliation wicri:level="1"><nlm:affiliation>a Servicio Epidemiología y Prevención , DG Salud Pública Servicio Canario de Salud , Las Palmas , Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>a Servicio Epidemiología y Prevención , DG Salud Pública Servicio Canario de Salud , Las Palmas </wicri:regionArea><wicri:noRegion>Las Palmas </wicri:noRegion></affiliation></author><author><name sortKey="Ortiz De Lejarazu, Raul" sort="Ortiz De Lejarazu, Raul" uniqKey="Ortiz De Lejarazu R" first="Raúl" last="Ortiz De Lejarazu">Raúl Ortiz De Lejarazu</name><affiliation wicri:level="1"><nlm:affiliation>b National Influenza Center , Servicio Microbiología Hospital Clínico Valladolid , Valladolid , Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>b National Influenza Center , Servicio Microbiología Hospital Clínico Valladolid , Valladolid </wicri:regionArea><wicri:noRegion>Valladolid </wicri:noRegion></affiliation></author><author><name sortKey="Reina, Jordi" sort="Reina, Jordi" uniqKey="Reina J" first="Jordi" last="Reina">Jordi Reina</name><affiliation wicri:level="1"><nlm:affiliation>c Centro de Referencia de la Gripe , Servicio Microbiología Hospital Universitario Son Espases , Palma de Mallorca , Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>c Centro de Referencia de la Gripe , Servicio Microbiología Hospital Universitario Son Espases , Palma de Mallorca </wicri:regionArea><wicri:noRegion>Palma de Mallorca </wicri:noRegion></affiliation></author><author><name sortKey="Callejo, Daniel" sort="Callejo, Daniel" uniqKey="Callejo D" first="Daniel" last="Callejo">Daniel Callejo</name><affiliation wicri:level="1"><nlm:affiliation>d BAP Health Outcomes Research , Oviedo , Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>d BAP Health Outcomes Research , Oviedo </wicri:regionArea><wicri:noRegion>Oviedo </wicri:noRegion></affiliation></author><author><name sortKey="Cuervo, Jesus" sort="Cuervo, Jesus" uniqKey="Cuervo J" first="Jesús" last="Cuervo">Jesús Cuervo</name><affiliation wicri:level="1"><nlm:affiliation>d BAP Health Outcomes Research , Oviedo , Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>d BAP Health Outcomes Research , Oviedo </wicri:regionArea><wicri:noRegion>Oviedo </wicri:noRegion></affiliation></author><author><name sortKey="Morano Larragueta, Raul" sort="Morano Larragueta, Raul" uniqKey="Morano Larragueta R" first="Raúl" last="Morano Larragueta">Raúl Morano Larragueta</name><affiliation wicri:level="1"><nlm:affiliation>e Dpto. Evaluación de Medicamentos , GSK , Madrid , Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>e Dpto. Evaluación de Medicamentos , GSK , Madrid </wicri:regionArea><wicri:noRegion>Madrid </wicri:noRegion></affiliation></author></analytic><series><title level="j">Human vaccines & immunotherapeutics</title><idno type="eISSN">2164-554X</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent (MeSH)</term><term>Adult (MeSH)</term><term>Aged (MeSH)</term><term>Aged, 80 and over (MeSH)</term><term>Child (MeSH)</term><term>Child, Preschool (MeSH)</term><term>Cost of Illness (MeSH)</term><term>Cost-Benefit Analysis (MeSH)</term><term>Female (MeSH)</term><term>Humans (MeSH)</term><term>Infant (MeSH)</term><term>Influenza Vaccines (administration & dosage)</term><term>Influenza Vaccines (economics)</term><term>Influenza Vaccines (immunology)</term><term>Influenza, Human (economics)</term><term>Influenza, Human (epidemiology)</term><term>Influenza, Human (prevention & control)</term><term>Male (MeSH)</term><term>Middle Aged (MeSH)</term><term>Pregnancy (MeSH)</term><term>Spain (epidemiology)</term><term>Young Adult (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent (MeSH)</term><term>Adulte (MeSH)</term><term>Adulte d'âge moyen (MeSH)</term><term>Analyse coût-bénéfice (MeSH)</term><term>Coûts indirects de la maladie (MeSH)</term><term>Enfant (MeSH)</term><term>Enfant d'âge préscolaire (MeSH)</term><term>Espagne (épidémiologie)</term><term>Femelle (MeSH)</term><term>Grippe humaine (prévention et contrôle)</term><term>Grippe humaine (économie)</term><term>Grippe humaine (épidémiologie)</term><term>Grossesse (MeSH)</term><term>Humains (MeSH)</term><term>Jeune adulte (MeSH)</term><term>Mâle (MeSH)</term><term>Nourrisson (MeSH)</term><term>Sujet âgé (MeSH)</term><term>Sujet âgé de 80 ans ou plus (MeSH)</term><term>Vaccins antigrippaux (administration et posologie)</term><term>Vaccins antigrippaux (immunologie)</term><term>Vaccins antigrippaux (économie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="economics" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="economics" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Influenza, Human</term><term>Spain</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="économie" xml:lang="fr"><term>Grippe humaine</term><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Espagne</term><term>Grippe humaine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Child</term><term>Child, Preschool</term><term>Cost of Illness</term><term>Cost-Benefit Analysis</term><term>Female</term><term>Humans</term><term>Infant</term><term>Male</term><term>Middle Aged</term><term>Pregnancy</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Analyse coût-bénéfice</term><term>Coûts indirects de la maladie</term><term>Enfant</term><term>Enfant d'âge préscolaire</term><term>Femelle</term><term>Grossesse</term><term>Humains</term><term>Jeune adulte</term><term>Mâle</term><term>Nourrisson</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Influenza has a major impact on healthcare systems and society, but can be prevented using vaccination. The World Health Organization (WHO) currently recommends that influenza vaccines should include at least two virus A and one virus B lineage (trivalent vaccine; TIV). A new quadrivalent vaccine (QIV), which includes an additional B virus strain, received regulatory approval and is now recommended by several countries. The present study estimates the cost-effectiveness of replacing TIVs with QIV for risk groups and elderly population in Spain. A static, lifetime, multi-cohort Markov model with a one-year cycle time was adapted to assess the costs and health outcomes associated with a switch from TIV to QIV. The model followed a cohort vaccinated each year according to health authority recommendations, for the duration of their lives. National epidemiological data allowed the determination of whether the B strain included in TIVs matched the circulating one. Societal perspective was considered, costs and outcomes were discounted at 3% and one-way and probabilistic sensitivity analyses were performed. Compared to TIVs, QIV reduced more influenza cases and influenza-related complications and deaths during periods of B-mismatch strains in the TIV. The incremental cost-effectiveness ratio (ICER) was 8,748€/quality-adjusted life year (QALY). One-way sensitivity analysis showed mismatch with the B lineage included in the TIV was the main driver for ICER. Probabilistic sensitivity analysis shows ICER below 30,000€/QALY in 96% of simulations. Replacing TIVs with QIV in Spain could improve influenza prevention by avoiding B virus mismatch and provide a cost-effective healthcare intervention.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27184622</PMID><DateCompleted><Year>2017</Year><Month>10</Month><Day>23</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2164-554X</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>9</Issue><PubDate><Year>2016</Year><Month>09</Month></PubDate></JournalIssue><Title>Human vaccines & immunotherapeutics</Title><ISOAbbreviation>Hum Vaccin Immunother</ISOAbbreviation></Journal><ArticleTitle>Cost-effectiveness analysis of quadrivalent influenza vaccine in Spain.</ArticleTitle><Pagination><MedlinePgn>2269-77</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/21645515.2016.1182275</ELocationID><Abstract><AbstractText>Influenza has a major impact on healthcare systems and society, but can be prevented using vaccination. The World Health Organization (WHO) currently recommends that influenza vaccines should include at least two virus A and one virus B lineage (trivalent vaccine; TIV). A new quadrivalent vaccine (QIV), which includes an additional B virus strain, received regulatory approval and is now recommended by several countries. The present study estimates the cost-effectiveness of replacing TIVs with QIV for risk groups and elderly population in Spain. A static, lifetime, multi-cohort Markov model with a one-year cycle time was adapted to assess the costs and health outcomes associated with a switch from TIV to QIV. The model followed a cohort vaccinated each year according to health authority recommendations, for the duration of their lives. National epidemiological data allowed the determination of whether the B strain included in TIVs matched the circulating one. Societal perspective was considered, costs and outcomes were discounted at 3% and one-way and probabilistic sensitivity analyses were performed. Compared to TIVs, QIV reduced more influenza cases and influenza-related complications and deaths during periods of B-mismatch strains in the TIV. The incremental cost-effectiveness ratio (ICER) was 8,748€/quality-adjusted life year (QALY). One-way sensitivity analysis showed mismatch with the B lineage included in the TIV was the main driver for ICER. Probabilistic sensitivity analysis shows ICER below 30,000€/QALY in 96% of simulations. Replacing TIVs with QIV in Spain could improve influenza prevention by avoiding B virus mismatch and provide a cost-effective healthcare intervention.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>García</LastName><ForeName>Amos</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>a Servicio Epidemiología y Prevención , DG Salud Pública Servicio Canario de Salud , Las Palmas , Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ortiz de Lejarazu</LastName><ForeName>Raúl</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>b National Influenza Center , Servicio Microbiología Hospital Clínico Valladolid , Valladolid , Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reina</LastName><ForeName>Jordi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>c Centro de Referencia de la Gripe , Servicio Microbiología Hospital Universitario Son Espases , Palma de Mallorca , Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Callejo</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>d BAP Health Outcomes Research , Oviedo , Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cuervo</LastName><ForeName>Jesús</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>d BAP Health Outcomes Research , Oviedo , Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morano Larragueta</LastName><ForeName>Raúl</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>e Dpto. Evaluación de Medicamentos , GSK , Madrid , Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>05</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hum Vaccin Immunother</MedlineTA><NlmUniqueID>101572652</NlmUniqueID><ISSNLinking>2164-5515</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017281" MajorTopicYN="Y">Cost of Illness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003362" MajorTopicYN="Y">Cost-Benefit Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013030" MajorTopicYN="N">Spain</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">QIV</Keyword><Keyword MajorTopicYN="Y">cost-effectiveness analysis</Keyword><Keyword MajorTopicYN="Y">costs and cost analysis</Keyword><Keyword MajorTopicYN="Y">healthcare costs</Keyword><Keyword MajorTopicYN="Y">human</Keyword><Keyword MajorTopicYN="Y">influenza</Keyword><Keyword MajorTopicYN="Y">influenza B virus</Keyword><Keyword MajorTopicYN="Y">influenza vaccines</Keyword><Keyword MajorTopicYN="Y">vaccines</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>5</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>5</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>10</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27184622</ArticleId><ArticleId IdType="doi">10.1080/21645515.2016.1182275</ArticleId><ArticleId IdType="pmc">PMC5027707</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>PLoS One. 2012;7(2):e31696</Citation><ArticleIdList><ArticleId IdType="pubmed">22348122</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2012 Jan;12(1):36-44</Citation><ArticleIdList><ArticleId IdType="pubmed">22032844</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Med. 2013 Jun 25;11:153</Citation><ArticleIdList><ArticleId IdType="pubmed">23800265</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Clin (Barc). 1999;112 Suppl 1:79-85</Citation><ArticleIdList><ArticleId IdType="pubmed">10618804</ArticleId></ArticleIdList></Reference><Reference><Citation>Health Technol Assess. 2003;7(35):iii-iv, xi-xiii, 1-170</Citation><ArticleIdList><ArticleId IdType="pubmed">14609480</ArticleId></ArticleIdList></Reference><Reference><Citation>An Pediatr (Barc). 2006 Sep;65(3):211-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16956499</ArticleId></ArticleIdList></Reference><Reference><Citation>Health Technol Assess. 2009 Feb;13(11):iii, ix-xii, 1-246</Citation><ArticleIdList><ArticleId IdType="pubmed">19215705</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2014 Jun 06;9(6):e98437</Citation><ArticleIdList><ArticleId IdType="pubmed">24905235</ArticleId></ArticleIdList></Reference><Reference><Citation>Transplantation. 2007 Oct 15;84(7):851-6</Citation><ArticleIdList><ArticleId IdType="pubmed">17984837</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2013;8(3):e60477</Citation><ArticleIdList><ArticleId IdType="pubmed">23555979</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Infect Dis. 2013 Jan 22;13:25</Citation><ArticleIdList><ArticleId IdType="pubmed">23339290</ArticleId></ArticleIdList></Reference><Reference><Citation>Cochrane Database Syst Rev. 2014 Mar 13;(3):CD001269</Citation><ArticleIdList><ArticleId IdType="pubmed">24623315</ArticleId></ArticleIdList></Reference><Reference><Citation>Enferm Infecc Microbiol Clin. 2015 Jan;33(1):22-6</Citation><ArticleIdList><ArticleId IdType="pubmed">24556268</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Clin Microbiol Infect Dis. 2000 Nov;19(11):834-42</Citation><ArticleIdList><ArticleId IdType="pubmed">11152308</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Health Econ. 2010 Oct;11(5):513-20</Citation><ArticleIdList><ArticleId IdType="pubmed">20405159</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2010 Sep 7;28 Suppl 4:D45-53</Citation><ArticleIdList><ArticleId IdType="pubmed">20713260</ArticleId></ArticleIdList></Reference><Reference><Citation>Gac Sanit. 2002 Jul-Aug;16(4):334-43</Citation><ArticleIdList><ArticleId IdType="pubmed">12113733</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2010 Mar 10;303(10):943-50</Citation><ArticleIdList><ArticleId IdType="pubmed">20215608</ArticleId></ArticleIdList></Reference><Reference><Citation>Gac Sanit. 2006 Mar-Apr;20(2):101-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16753086</ArticleId></ArticleIdList></Reference><Reference><Citation>J Paediatr Child Health. 2000 Aug;36(4):332-5</Citation><ArticleIdList><ArticleId IdType="pubmed">10940165</ArticleId></ArticleIdList></Reference><Reference><Citation>Value Health. 2012 Sep-Oct;15(6):796-803</Citation><ArticleIdList><ArticleId IdType="pubmed">22999128</ArticleId></ArticleIdList></Reference><Reference><Citation>Cochrane Database Syst Rev. 2010 Feb 17;(2):CD004876</Citation><ArticleIdList><ArticleId IdType="pubmed">20166072</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacoeconomics. 2008;26(1):45-56</Citation><ArticleIdList><ArticleId IdType="pubmed">18088158</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Infect Dis. 2007 Jan;11(1):40-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16678464</ArticleId></ArticleIdList></Reference><Reference><Citation>Cochrane Database Syst Rev. 2012 Aug 15;(8):CD004879</Citation><ArticleIdList><ArticleId IdType="pubmed">22895945</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2012 Mar 2;30(11):1993-8</Citation><ArticleIdList><ArticleId IdType="pubmed">22226861</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Espagne</li></country></list><tree><country name="Espagne"><noRegion><name sortKey="Garcia, Amos" sort="Garcia, Amos" uniqKey="Garcia A" first="Amos" last="García">Amos García</name></noRegion><name sortKey="Callejo, Daniel" sort="Callejo, Daniel" uniqKey="Callejo D" first="Daniel" last="Callejo">Daniel Callejo</name><name sortKey="Cuervo, Jesus" sort="Cuervo, Jesus" uniqKey="Cuervo J" first="Jesús" last="Cuervo">Jesús Cuervo</name><name sortKey="Morano Larragueta, Raul" sort="Morano Larragueta, Raul" uniqKey="Morano Larragueta R" first="Raúl" last="Morano Larragueta">Raúl Morano Larragueta</name><name sortKey="Ortiz De Lejarazu, Raul" sort="Ortiz De Lejarazu, Raul" uniqKey="Ortiz De Lejarazu R" first="Raúl" last="Ortiz De Lejarazu">Raúl Ortiz De Lejarazu</name><name sortKey="Reina, Jordi" sort="Reina, Jordi" uniqKey="Reina J" first="Jordi" last="Reina">Jordi Reina</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippeEspagneV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000158 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000158 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= GrippeEspagneV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:27184622
|texte= Cost-effectiveness analysis of quadrivalent influenza vaccine in Spain.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:27184622" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeEspagneV1
| This area was generated with Dilib version V0.6.37. |  |